Analysis of the Mechanisms of Protective Humoral Immunity in Response to the Pneumococcal Vaccine
| Status: | Completed |
|---|---|
| Conditions: | Healthy Studies |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | 20 - 70 |
| Updated: | 4/21/2016 |
| Start Date: | July 2007 |
| End Date: | January 2010 |
The lack of clear guidelines and studies addressing the proper response to the pneumococcal
vaccine (Pneumovax ®) has hampered our ability to diagnosis and care for our
immunodeficiency patients. Should an age matched normal response range to the Pneumovax ® be
established, it would have a profound impact in the diagnosis, safety and care of
immunodeficiency patients. Moreover, characterizing the B cell compartments response to the
Pneumovax ® may better delineate the mechanism of protective immunity from Pneumovax ® and
provide an additional tool for the diagnosis and care for immunodeficiency patients.
vaccine (Pneumovax ®) has hampered our ability to diagnosis and care for our
immunodeficiency patients. Should an age matched normal response range to the Pneumovax ® be
established, it would have a profound impact in the diagnosis, safety and care of
immunodeficiency patients. Moreover, characterizing the B cell compartments response to the
Pneumovax ® may better delineate the mechanism of protective immunity from Pneumovax ® and
provide an additional tool for the diagnosis and care for immunodeficiency patients.
The ability to respond to a polysaccharide vaccine antigen is an integral part of evaluating
a patient with immunodeficiency. The pneumococcal vaccine (Pneumovax ®) remains the only
readily available and the most widely used unconjugated polysaccharide vaccine. Although the
pneumococcal vaccine is widely used test the immune systems response to a polysaccharide
antigen, no clear guidelines or studies exist to what is considered a proper response to the
Pneumovax ®. Immunoglobulin M (IgM) memory B cells are thought to play an important role in
protection against pneumococcal disease. It is not known to what extent the ability of B
cells to be activated in response to pneumococcal vaccination contributes to protective
immunity. To address these issues, the following two specific aims are proposed:
Specific Aim 1. Assess Immunoglobulin G (IgG) antibodies to pneumococcus pre- and
post-pneumococcal immunization in healthy controls Specific Aim 2. Analysis of B cell
subsets in blood of healthy controls pre-and post-pneumococcal immunization to identify
changes in memory B cell, class switched and activated B cells.
a patient with immunodeficiency. The pneumococcal vaccine (Pneumovax ®) remains the only
readily available and the most widely used unconjugated polysaccharide vaccine. Although the
pneumococcal vaccine is widely used test the immune systems response to a polysaccharide
antigen, no clear guidelines or studies exist to what is considered a proper response to the
Pneumovax ®. Immunoglobulin M (IgM) memory B cells are thought to play an important role in
protection against pneumococcal disease. It is not known to what extent the ability of B
cells to be activated in response to pneumococcal vaccination contributes to protective
immunity. To address these issues, the following two specific aims are proposed:
Specific Aim 1. Assess Immunoglobulin G (IgG) antibodies to pneumococcus pre- and
post-pneumococcal immunization in healthy controls Specific Aim 2. Analysis of B cell
subsets in blood of healthy controls pre-and post-pneumococcal immunization to identify
changes in memory B cell, class switched and activated B cells.
Inclusion Criteria:
- Patients from 20 to 70 years of age
Exclusion Criteria:
- Previous or current diagnosis of an immunodeficiency (primary and secondary)
- Previous or current diagnosis of a rheumatological disorders (Rheumatoid arthritis,
Lupus, Sjögren, vasculitis), cancer, diabetes, active infection and/or other chronic
diseases (multiple sclerosis, etc)
- Current or previous use (within that last 6 months) of systemic/inhaled
corticosteroids, sulfasalazine, and other immunosuppressive agents (cyclosporin,
methotrexate, CellCept) anti-convulsants (phenytoin, carbamazepine), gold,
d-penicillamine, and anti-malarials (quinine, chloroquine, hydroxychloroquine)
- Pregnancy
We found this trial at
1
site
Click here to add this to my saved trials
